Molecular Targeted Therapy

CHICAGO — David Andrew Sallman, MD, myeloid section head at Moffitt Cancer Center, talked about two presentations on molecular targeted therapy from the ASCO Annual Meeting.

In this video, Lillian L. Siu, MD, FRCPC, discussed a panel discussion at 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on the topic of in drug development roadblocks.

In this video, Lillian L. Siu, MD, FRCPC, discusses two keynote presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

ASCO has named molecular profiling driving progress in gastrointestinal cancer as its Advance of the Year, acknowledging improvements in treatment that have resulted from molecular testing of patients’ tumors.

Healio spoke with Fred R. Hirsch, MD, PhD, professor of medicine and pathology at the University of Colorado Cancer Center in Denver and CEO of the International Association for the Study of Lung Cancer, about the multiple clinical trials being performed in the United States and Europe that study biomarkers and personalized medicine in the field of lung cancer.

A precision medicine approach to therapy significantly extended survival for patients with pancreatic cancer compared with standard chemotherapy, according to results of a retrospective study published in The Lancet Oncology.

Maintenance chemotherapy following initial treatment appeared to be more beneficial for patients with metastatic colorectal cancer than continuing a full induction regimen until disease progression, according to results of a meta-analysis of randomized clinical trials published in JAMA Oncology.